Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
Atavistik Bio, Inc
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
University of Chicago
Dana-Farber Cancer Institute
University of Texas Southwestern Medical Center
University of Pennsylvania
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Amgen
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
NeoTX Therapeutics Ltd.
City of Hope Medical Center
Thomas Jefferson University
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Columbia University
Dana-Farber Cancer Institute
Theratechnologies
Ohio State University Comprehensive Cancer Center
Turku University Hospital
Agenus Inc.
Carisma Therapeutics Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
National University Hospital, Singapore